Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.

    ... two randomized clinical trials, the demethylating agent azacitidine has demonstrated a reduced risk of transformation to AML, ... aims to provide practical recommendations for the use of azacitidine and the management of its side effects in patients with MDS, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies

    ... investigate the impact of prior-to-transplantation azacitidine (AZA) on patient outcome after allogeneic stem-cell ...

    Research Article last updated 11/05/2012 - 8:57am.

  3. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

    ... This analysis compared azacitidine (AZA) to conventional care regimens (CCR) and their associated ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Adverse effects of azacitidine: onset, duration, and treatment

    ... with survivals of close to only 1 year. The use of azacitidine , a DNA methyltransferase inhibitor, in this group of patients ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Azacitidine adverse effects in patients with myelodysplastic syndromes

    ... Azacitidine is now considered one of the standard-of-care agents for ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications

    ... leukemia (AML). Although the hypomethylating agent azacitidine prolongs survival among patients with higher risk (HR)-MDS ...

    Research Article last updated 02/21/2017 - 9:34am.

  7. Effectiveness of azacitidine in higher-risk myelodysplastic syndromes

    Journal Title:  Leukemia Primary Author:  Dinmohamed AG Author(s):  Dinmohame...

    Research Article last updated 06/23/2016 - 9:31am.

  8. Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights

    ... in TET2 molecule show better response to treatment with azacitidine . IDH and DNMT3A mutations are associated with a good response ...

    Research Article last updated 02/01/2017 - 8:15am.

  9. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

    ... retrospective cohort of 282 higher-risk MDS treated with azacitidine , including 32 patients who concomitantly received an ESA for a median of 5.8months after azacitidine onset. Forty-four percent of ESA and 29% of no-ESA patients reached ...

    Research Article last updated 07/28/2014 - 9:30am.

  10. MDS Follows Two Misdiagnoses

    ... erythropoietin (Procrit®), G-CSF, (Neupogen®), azacitidine , (Vidaza®) and deferoxamine (Desferal®). My hemoglobin ... so far this year which is more than usual for me and my last azacitidine (Vidaza®) treatment in June didn't seem to have much benefit. ...

    Patient Chronicle last updated 12/27/2016 - 7:23am.